<p>The Government is continuing work with stakeholders to assess the full costs of implementing the ‘safety features’ under the Falsified Medicines Directive in the United Kingdom taking account of the different approaches and use of the flexibilities allowed by the delegated regulation.</p><p> </p><p>The European Union has published an assessment of the overall impact of the Delegated Regulation, which includes information on hospitals, doctors and pharmacy, and is available at the following link:</p><p> </p><p><a href="http://ec.europa.eu/smart-regulation/impact/ia_carried_out/docs/ia_2015/swd_2015_0189_en.pdf" target="_blank">http://ec.europa.eu/smart-regulation/impact/ia_carried_out/docs/ia_2015/swd_2015_0189_en.pdf</a></p>